TW202404966A - 蘭尼菲諾(lanifibranor)之晶型 - Google Patents

蘭尼菲諾(lanifibranor)之晶型 Download PDF

Info

Publication number
TW202404966A
TW202404966A TW112112450A TW112112450A TW202404966A TW 202404966 A TW202404966 A TW 202404966A TW 112112450 A TW112112450 A TW 112112450A TW 112112450 A TW112112450 A TW 112112450A TW 202404966 A TW202404966 A TW 202404966A
Authority
TW
Taiwan
Prior art keywords
ranifino
type
beta
pxrd
pxrd pattern
Prior art date
Application number
TW112112450A
Other languages
English (en)
Chinese (zh)
Inventor
弗列德瑞克 貝爾
白納伊沙 博比亞
Original Assignee
法商因文帝華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商因文帝華公司 filed Critical 法商因文帝華公司
Publication of TW202404966A publication Critical patent/TW202404966A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW112112450A 2022-04-05 2023-03-31 蘭尼菲諾(lanifibranor)之晶型 TW202404966A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPEP22305456 2022-04-05
EP22305456 2022-04-05

Publications (1)

Publication Number Publication Date
TW202404966A true TW202404966A (zh) 2024-02-01

Family

ID=81326293

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112112450A TW202404966A (zh) 2022-04-05 2023-03-31 蘭尼菲諾(lanifibranor)之晶型

Country Status (14)

Country Link
US (1) US20250243192A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504725A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511847A (cg-RX-API-DMAC7.html)
KR (1) KR20250002337A (cg-RX-API-DMAC7.html)
CN (1) CN119301120A (cg-RX-API-DMAC7.html)
AR (1) AR128985A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023250118A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247273A1 (cg-RX-API-DMAC7.html)
IL (1) IL316075A (cg-RX-API-DMAC7.html)
MX (1) MX2024012348A (cg-RX-API-DMAC7.html)
PY (1) PY2324870A (cg-RX-API-DMAC7.html)
TW (1) TW202404966A (cg-RX-API-DMAC7.html)
UY (1) UY40216A (cg-RX-API-DMAC7.html)
WO (1) WO2023194339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022325334A1 (en) * 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof
JP2026501899A (ja) 2023-01-19 2026-01-16 インベンティバ ラニフィブラノール製剤
WO2024251730A1 (en) 2023-06-05 2024-12-12 Inventiva Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver condition
AR133887A1 (es) * 2023-09-22 2025-11-12 Inventiva Método de fabricación de lanifibranor
IL330214A (en) 2023-12-21 2026-08-01 Inventiva Combination therapy for the prevention and/or treatment of liver disease
AU2024409290A1 (en) 2023-12-21 2026-08-06 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor
WO2025191117A1 (en) 2024-03-15 2025-09-18 Inventiva Prevention of blood disorders in patient treated with a ppar agonist
TW202604485A (zh) 2024-05-17 2026-02-01 法商因文帝華公司 患有肝損傷患者肝疾病之治療
WO2026115290A1 (en) 2024-11-28 2026-06-04 Inventiva Non-invasive monitoring of nash treatment with lanifibranor
WO2026125286A1 (en) 2024-12-09 2026-06-18 Inventiva Combinations comprising lanifibranor and a glp-1/gip/glucagon triple receptor agonist for use in the treatment of liver diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
WO2022143479A1 (zh) 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
US20240246949A1 (en) 2021-06-10 2024-07-25 Teva Pharmaceuticals International Gmbh Solid state forms of lanifibranor and process for preparation thereof
CN115466252A (zh) 2021-06-11 2022-12-13 上海希迈医药科技有限公司 一种Lanifibranor的晶型及其制备方法
AU2022325334A1 (en) 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
MX2024012348A (es) 2024-11-08
JP2025511847A (ja) 2025-04-16
EP4504725A1 (en) 2025-02-12
WO2023194339A1 (en) 2023-10-12
UY40216A (es) 2023-10-31
CA3247273A1 (en) 2023-10-12
IL316075A (en) 2024-12-01
PY2324870A (es) 2023-10-27
CN119301120A (zh) 2025-01-10
US20250243192A1 (en) 2025-07-31
KR20250002337A (ko) 2025-01-07
AR128985A1 (es) 2024-07-03
AU2023250118A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
US20250243192A1 (en) Crystalline form of lanifibranor
AU2015214182B2 (en) Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP2426118B1 (en) Methods of making polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
KR102347340B1 (ko) 트레프로스티닐의 고체 형태
JP2020519654A (ja) ベルベリンウルソデオキシコール酸の固体形態ならびにその組成物および方法
KR20170033684A (ko) 리나글립틴 결정형 및 이의 제조방법
US20120142693A1 (en) Crystalline compound of 7-[(3r)-3-amino-1-oxo-4-(2, 4, 5-trifluorphenyl)butyl]-5, 6, 7, 8-tetrahydro-3-(tri fluormethyl)-1, 2, 4 -triazolo[4,3-a]pyrazin
JP2024515770A (ja) タファミジスの固体形態及びその製造方法
JP2006521340A (ja) ロシグリタゾン・マレイン酸塩の多形体の製法
EA052550B1 (ru) Кристаллическая форма ланифибранора
HK40120719A (en) Crystalline form of lanifibranor
WO2018172950A1 (en) Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate
WO2026074067A1 (en) Solid forms of a gamma-secretase modulator
EP4608832A1 (en) 2-(4-(2-(7, 8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1h-indol-5-yl)piperidin-1-yl)acetamide salt and crystalline forms thereof
HK40057492A (en) Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
JP2025537478A (ja) ジメチル-2,3-ジヒドロ-1h-インデン誘導体の新規塩およびその製造方法
AU2013203194B2 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN122003412A (zh) 制备拉尼兰诺的方法
CN1922196A (zh) 一种医药化合物的结晶形式
HK1167646B (en) Methods of making polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione